Clariant Ag · SIX:CLN
Clariant — Q1 2020 Earnings Presentation
20 slides from Clariant's earnings presentation, Apr 30, 2020
Slide 1: First Quarter 2020
First Quarter 2020 30 APRIL 2020
Slide 2: Disclaimer
2 First Quarter 2020 30 April 2020 Disclaimer This presentation contains certain statements that are neither reported financial results nor other historical information. This presentation also includes forward-looking statements. Because these forward-looking statements are subject to risks and unce
Slide 3: First Quarter 2020 – Highlights
3 First Quarter 2020 30 April 2020 First Quarter 2020 – Highlights Q1 2020 vs. Q1 2019, all figures continuing operations SALES 1 019 - 6 % − Sales from continuing operations decreased by 6 % in local currency in a difficult environment in CHF m in LC* y-o-y EBITDA 157 - 14 % 15.4 % − Resilient EBIT
Slide 4: Sales Development & Mix
4 First Quarter 2020 30 April 2020 Sales Development & Mix All figures continuing operations − Q1 2020 sales down by 6 % in local currency, Q1 2020 SALES in CHF m versus a high comparison base 1 164 -7% − Weaker global demand environment amid COVID-19 impact +1% +0% -6% − Growth in Natural Resources
Slide 5: Sales Distribution by Region
5 First Quarter 2020 30 April 2020 Sales Distribution by Region Emerging markets All figures continuing operations Mature markets Q1 2020 SALES CHF 1 019 m − In Q1 2020, sales development in Asia was in CHF m robust despite impact from COVID-19 pandemic ASIA-PACIFIC NORTH AMERICA in China 259 / - 1
Slide 6: Care Chemicals
6 First Quarter 2020 30 April 2020 Care Chemicals Q1 2020 Q1 2019 % CHF % LC* − Q1 2020 sales decreased by 14 % in LC* versus the strong Sales in CHF m 387 480 - 19 % - 14 % results generated in Q1 2019 EBITDA in CHF m 69 94 - 27 % − Consumer Care sales declined in a low single-digit range, EBITDA m
Slide 7: Catalysis
7 First Quarter 2020 30 April 2020 Catalysis Q1 2020 Q1 2019 % CHF % LC* − Q1 2020 sales decreased by 6 % in LC* against a very Sales in CHF m 182 203 - 10 % -6% strong Q1 2019 EBITDA in CHF m 24 44 - 45 % − This development is partially attributable to the previously EBITDA margin 13.2 % 21.7 % com
Slide 8: Natural Resources
8 First Quarter 2020 30 April 2020 Natural Resources Q1 2020 Q1 20191 % CHF % LC* − Q1 2020 sales increased by 2 % in LC* Sales in CHF m 450 481 -6% +2% − Oil and Mining Services delivered double-digit sales EBITDA in CHF m 86 75 + 15 % expansion in LC*, with higher sales in all regions EBITDA margi
Slide 9: First Quarter 2020 – EBITDA Development
9 First Quarter 2020 30 April 2020 First Quarter 2020 – EBITDA Development All figures continuing operations Q1 EBITDA / margin in CHF m / in % of sales − The EBITDA margin remained robust at 15.7 % 15.4 % 20.0 % 15.4 % (versus 15.7 %) 19.0 % 230 18.0 % 17.0 % 16.0 % − Q1 2020 absolute EBITDA decrea
Slide 10: Outlook
a CLARIANT Outlook what is precious to you?
Slide 11: Clariant focuses on mitigating COVID-19 pandemic impact while generating resilient performance
11 First Quarter 2020 30 April 2020 Clariant focuses on mitigating COVID-19 pandemic impact while generating resilient performance and continuing transformation − Sales declined by 6 % in LC* in Q1 2020 in a particularly turbulent environment − Continuing operations EBITDA nevertheless remained resi
Slide 12: Back-up Slides
a CLARIANT Back-up Slides what is precious to you?
Slide 13: A More Focused, High Value Specialty Portfolio
13 First Quarter 2020 30 April 2020 A More Focused, High Value Specialty Portfolio Continuing Operations: Sales growth Sales growth Sales growth expectation p.a. 5-7% expectation p.a. 6-9% expectation p.a. 5-7% EBITDA EBITDA EBITDA 19 - 21 % 26 - 30 % 18 - 20 % margin ambition margin ambition margin
Slide 14: Discontinued Operations (Masterbatches and Pigments)
14 First Quarter 2020 30 April 2020 Discontinued Operations (Masterbatches and Pigments) Q1 2020 Q1 20191 % CHF % LC* − Q1 2020 sales decreased by 6 % in LC* and 12 % Swiss Sales in CHF m 485 551 - 12 % -6% francs, but like-for-like (excl. Healthcare Packaging in Q1 2019) organic Q1 2020 sales remai
Slide 15: First Quarter 2020 – Sales and EBITDA by Business Area
15 First Quarter 2020 30 April 2020 First Quarter 2020 – Sales and EBITDA by Business Area Sales to 3rd parties EBITDA First Quarter in CHF m 2020 2019* % LC** 2020 2019* % CHF Care Chemicals 387 480 - 14 % 69 94 - 27 % margin 17.8 % 19.6 % Catalysis 182 203 -6% 24 44 - 45 % margin 13.2 % 21.7 % Nat
Slide 16: Full Year 2019 – Sales and EBITDA by Business Area
16 First Quarter 2020 30 April 2020 Full Year 2019 – Sales and EBITDA by Business Area Sales to 3rd parties EBITDA Full Year in CHF m 2019 2018 % LC* 2019 2018 % CHF Care Chemicals 1 600 1 665 -1% 282 314 - 10 % margin 17.6 % 18.9 % Catalysis 925 861 +9% 212 185 + 15 % margin 22.9 % 21.5 % Natural R
Slide 17: Update on COVID-19 mitigation measures
17 Full Year Results 2019 30 April 2020 Update on COVID-19 mitigation measures • Employee safety – only a few recorded infections in quarantine so far, cases of infection kept low thanks to social distancing, home office arrangements and a travel ban governed by Clariant’s global emergency managemen
Slide 18: Calendar of Upcoming Corporate Events
18 First Quarter 2020 30 April 2020 Calendar of Upcoming Corporate Events 30 July 2020 First Half 2020 Reporting 29 October 2020 Nine Months 2020 Reporting 11 February 2021 Full Year 2020 Reporting
Slide 19: IR Contacts
19 First Quarter 2020 30 April 2020 IR Contacts Maria Ivek Phone: +41 61 469 63 73 Senior Investor Relations Officer Email: [email protected] Alexander Kamb Investor Relations Officer
Slide 20: Our iPad App
20 First Quarter 2020 30 April 2020 Our iPad App Download it here: iPad App: www.clariant.com/IRapp